lyophilized powder raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-11-10. Anything still debated is marked as such rather than presented as settled.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Average life expectancy following diagnosis is about four years. Updated international guidelines were published in 2022, which resulted in some simplification in diagnosis and the removal of antacids as a possible adjunct therapy.
It also introduced new menu items including a turkey burger, tater tots and a "triple double", although the latter prompted a copyright infringement lawsuit from In-n-Out Burger, as well as a class-action lawsuit for false advertising. The restaurant faced difficulties in continuing to grow, in part as shoppers began to shift away from shopping in traditional retail centers where its restaurants were concentrated. At the same time, larger restaurant chains increased their efforts to grow sales and brought on higher-quality menu items to compete with Smashburger and restaurants like it. Subsequently, Smashburger saw its overall same-store sales decline as a number of other local "better burger" concepts grew. Crane left as CEO in April 2016, and was replaced by Mike Nolan, but he resigned nine months later and Ryan took over the role. The restaurant thus condensed its expansion strategy to focus on existing markets and began mentorship programs to develop leadership talent from within its ranks of workers. It also bought back some franchise restaurants in several major markets. Smashburger competitors like Shake Shack and Five Guys experienced many of these difficulties, as well. In 2016, Smashburger was estimated to have $338.3 million in sales. On 13 February 2018, Jollibee increased its ownership stake to 85 percent of Smashburger in another $100 million deal. In making the acquisition, the companies said the move would allow Smashburger to further expand its presence in southeast Asia.
=== Sale in Japan === The alcoholic beverage industry in Japan is large. For example, in fiscal year 2013, Suntory, one of the country's largest beverage companies, recorded sales of 570.7 billion yen (about US$4.7 billion) in alcoholic beverages, excluding wine. Currently, the sales revenue from powdered alcohol has been too small to affect the sales of liquid-alcohol companies. Additionally, powdered alcohol's market share is currently too small to be considered as a statistical item in Japanese tax reports. Powdered alcohol is found in some mass production foods, used in small amounts (as are other additives).
==== 2024 ==== Researchers demonstrated antibody-mediated depletion of myeloid-biased hematopoietic stem cells against immune system aging with mice. An experiment by researchers at Imperial College London, the MRC London Institute of Medical Sciences, and Duke–NUS Medical School found that reduction in levels of the protein interleukin 11, which increases in the body with age and in excess is responsible for increased inflammation, reversed some aspects of aging in mice. The experiment, which involved genetically engineering some mice to block the production of the protein and allowing others to reach middle age before giving them a drug to eliminate it from their bodies, increased their lifespans by 20–25% and reversed numerous effects of aging. Precious3GPT, an artificial intelligence model designed to assist in aging research and drug discovery, was launched. A study by scientists at Stanford University found that rather than being a solely gradual and linear process, aging accelerates dramatically at two points in a human lifetime. The study, which tracked thousands of different molecules in 108 people aged between 25 and 75, found that age-related changes rise substantially in two waves, with the first occurring at around age 44 and the second at around age 60.
== Forensic detection == Worldwide, certain traditional Chinese medicines contain wild bear bile, banned under CITES legislation. Dip sticks, similar to common pregnancy tests, have been developed to detect the presence of bear albumin in traditional medicine products, indicating that bear bile had been used in their creation.
Sources: en.wikipedia.org
Zverev then made only modest achievements in the succeeding weeks, losing to Learner Tien in the second round of the Mexican Open, to Tallon Griekspoor in the second round of Indian Wells, to Arthur Fils in the fourth round of the Miami Open, and to Matteo Berrettini in Monte-Carlo. In April, Zverev won his 3rd title in Munich and 24th overall on his birthday, winning in straight sets over Ben Shelton. Zverev was presented his trophy BMW by Dominic Thiem, and reclaimed the world No. 2 ranking from Alcaraz. The next week, he reached the round of 16 at the Madrid Open. During his third round match, Zverev was given a code violation for taking a photo of the ball mark of shot which Zverev considered to have been erroneously called in. Later, social media posts from the ATP Tour suggested that the Hawk-Eye call was correct and that Zverev likely took a picture of a different mark. Following this, Zverev failed to defend either his titles in Rome and Hamburg with a straight sets loss against an in-form Lorenzo Musetti and a three-set loss against Alexandre Müller, respectively. At the French Open where he was defending finalist points, Zverev advanced to the quarterfinals, where he was defeated by Novak Djokovic in a four-set match. On the grass, Zverev reached his third final of the year in Stuttgart, losing to Taylor Fritz in straight sets in his fifth consecutive loss against the American. He then reached the semifinals against Daniil Medvedev in Halle, losing in three sets.
During the remainder of the war, Cossack units were dismounted to fight in trenches, held in reserve to exploit a rare breakthrough, or assigned various duties in the rear. Those duties included rounding up deserters, providing escorts to war prisoners, and razing villages and farms in accordance with Russia's scorched earth policy.
Cephalopods are widely regarded as the most intelligent of the invertebrates and have well-developed senses and large brains (larger than those of gastropods). The nervous system of cephalopods is the most complex of the invertebrates and their brain-to-body-mass ratio falls between that of endothermic and ectothermic vertebrates. Captive cephalopods have been known to climb out of their aquaria, maneuver a distance of the lab floor, enter another aquarium to feed on captive crabs, and return to their own aquarium. The brain is protected in a cartilaginous cranium. The giant nerve fibers of the cephalopod mantle have been widely used for many years as experimental material in neurophysiology; their large diameter (due to lack of myelination) makes them relatively easy to study compared with other animals. Many cephalopods are social creatures; when isolated from their own kind, some species have been observed shoaling with fish. Some cephalopods are able to fly through the air for distances of up to 50 metres (160 ft). While cephalopods are not particularly aerodynamic, they achieve these impressive ranges by jet-propulsion; water continues to be expelled from the funnel while the organism is in the air. The animals spread their fins and tentacles to form wings and actively control lift force with body posture. One species, Todarodes pacificus, has been observed spreading tentacles in a flat fan shape with a mucus film between the individual tentacles, while another, Sepioteuthis sepioidea, has been observed putting the tentacles in a circular arrangement.
== Applications == One of the potent applications of siRNAs is the ability to distinguish the target versus non-target sequence with a single-nucleotide difference. This approach has been considered therapeutically crucial for silencing dominant gain-of-function (GOF) disorders, where the mutant allele causing disease differs from the wild-type allele by a single nucleotide (nt). These types of siRNAs, which are capable of distinguishing a single-nucleotide difference, are termed allele-specific siRNAs. ASP-RNAi is an innovative category of RNAi with the objective of suppressing the dominant mutant allele while sparing expression of the corresponding normal allele with the specificity of single-nucleotide differences between the two. ASP-siRNAs are potentially a novel and better remedial alternative for the treatment of autosomal dominant genetic disorders, especially in cases where wild-type allele expression is crucial for organism survival, such as Huntington disease (HD), DYT1 dystonia (Gonzalez-Alegre et al. 2003, 2005), Alzheimer's disease (AD) (Sierant et al. 2011), Parkinson's disease (PD) (Takahashi et al. 2015), amyotrophic lateral sclerosis (ALS) (Schwarz et al. 2006), and Machado-Joseph disease (MJD) (Alves et al. 2008). Their therapeutic potential has also been assessed for various skin disorders like epidermolysis bullosa simplex (Atkinson et al. 2011), epidermolytic palmoplantar keratoderma (EPPK) (Lyu et al. 2016), and lattice corneal dystrophy type I (LCDI) (Courtney et al. 2014).
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.